Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Timely withdrawal of G-CSF reduced occurrence of thrombocytopenia during dose-dense chemotherapy
December 1st, 2005
Timely withdrawal of granulocyte colony stimulating factor (G-CSF) could reduce the occurrence of thrombocytopenia during dose-dense chemotherapy. "Post chemotherapy G-CSF reduces leucopenia, while G-CSF priming shortly before chemotherapy increases myelotoxicity. We performed a trial with a two-schedule crossover design to determine the optimal G-CSF schedule for densified 2-weekly chemotherapy," investigators in the Netherlands reported. "During 2-weekly chemotherapy days 1 and 2, G-CSF was given on days 3-10, with a G-CSF-free interval before the next chemotherapy cycle of 5 days, or on days 3-13, with a G-CSF-free interval of 2 days," explained...
Source: Women's Health Weekly (2005-12-01)
|
